中国基层医药
中國基層醫藥
중국기층의약
CHINESE JOURNAL OF PRIMARY MEDICINE AND PHARMACY
2014年
12期
1787-1788
,共2页
癌,非小细胞肺%神经内分泌化%热疗%药物疗法
癌,非小細胞肺%神經內分泌化%熱療%藥物療法
암,비소세포폐%신경내분비화%열료%약물요법
Carcinoma,non-small cell lung%Neuroendocrine differentiation%Thermotherapy%Drug therapy
目的 探讨热疗联合化疗治疗晚期非小细胞肺癌伴神经内分泌化(NSCLC-NED)的临床疗效.方法 回顾性分析16例NSCLC-NED患者的临床资料,所有患者接受含铂类联合方案化疗,同时给予局部热疗,随访其疗效及生存情况.结果 16例患者中部分缓解(PR)7例,稳定(SD)4例,近期有效率(RR)43.8％,1年生存率为37.5％ (6/16),生活质量改善率62.5％ (10/16).结论 神经内分泌分化是NSCLC生物学行为的重要指标,化疗联合热疗安全、有效.
目的 探討熱療聯閤化療治療晚期非小細胞肺癌伴神經內分泌化(NSCLC-NED)的臨床療效.方法 迴顧性分析16例NSCLC-NED患者的臨床資料,所有患者接受含鉑類聯閤方案化療,同時給予跼部熱療,隨訪其療效及生存情況.結果 16例患者中部分緩解(PR)7例,穩定(SD)4例,近期有效率(RR)43.8％,1年生存率為37.5％ (6/16),生活質量改善率62.5％ (10/16).結論 神經內分泌分化是NSCLC生物學行為的重要指標,化療聯閤熱療安全、有效.
목적 탐토열료연합화료치료만기비소세포폐암반신경내분비화(NSCLC-NED)적림상료효.방법 회고성분석16례NSCLC-NED환자적림상자료,소유환자접수함박류연합방안화료,동시급여국부열료,수방기료효급생존정황.결과 16례환자중부분완해(PR)7례,은정(SD)4례,근기유효솔(RR)43.8％,1년생존솔위37.5％ (6/16),생활질량개선솔62.5％ (10/16).결론 신경내분비분화시NSCLC생물학행위적중요지표,화료연합열료안전、유효.
Objective To study the clinical efficacy of thermotherapy combined chemotherapy in the treatment of the advanced non-small cell lung carcinoma with neuroendocrine differentiation (NSCLC-NED).Methods The clinical data of 16 patients with NSCLC-NED were retrospectively reviewed.To analyzed the efficacy and survival of these patients.All patients were treated by thermotherapy with the combined chemotherapy regiment of platinum agents.Results There were 7 partial responses and 4 stable disease,The overall response rate (RR) was 43.8％.The one year survival rate was 37.5％ (6/16).The improvement rate of quality of life was 62.5％ (10/16).Conclusion Neuroendocrine differentiation is an important indicator of biological behavior of NSCLC.Thermochemotherapy is an active regimen in the advanced NSCLC-NED with an acceptabe toxicity.
